MemorialCare Innovation Fund, a strategic investment company wholly owned by the MemorialCare Health System, has participated in a series B round of funding for eye stent specialist Ivantis worth $46.5m.
Ivantis, a US developer of stents used to lower eye pressure for glaucoma patients, has reported that it has raised $46.5m in a series B round of funding of which existing corporate venturing unit MemorialCare Innovation Fund, Ascension Ventures and EDBI, has participated. The capital will be allocated to ongoing costs related to its ongoing clinical trials. The company has raised over $63.3m to date.
According to the company, the final close of its round came from Vertex Ventures and…
